Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

 Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Shots:

  • The US FDA has put a partial clinical hold on P-II/III study of Inovio’s INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial because it has additional questions about the trial
  • Inovio is actively working to address the FDA’s questions and plans to respond in Oct’2020 after which the FDA will have ~30 days to notify the company about its decision as to proceed the trial or no
  • Additionally, the partial clinical hold does not impact the advancement of Inovio’s other product candidates in development

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post